Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 9/20 | 0.59 |
| ▸ | MAOB | P27338 | 3/20 | 0.49 |
| ▸ | MAOA | P21397 | 2/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21685531 | 0.87 | KDM1A (0.52) | KDM1AMAOBMAOALTA4HMAPK14 | |
| SCHEMBL2894914 | 0.84 | KDM1A (0.61) | KDM1AMAOBMAOALTA4HMAPK14 | |
| SCHEMBL24750717 | 0.84 | MAPT (0.49) | KDM1AMAOBMAOALTA4HMAPK14 | |
| SCHEMBL4540283 | 0.80 | KDM1A (0.56) | KDM1AMAOBMAOAMAPK14MAPT | |
| SCHEMBL30568467 | 0.80 | KDM1A (0.56) | KDM1AMAOBMAOAMAPTL3MBTL1 | |
| SCHEMBL2894699 | 0.79 | KDM1A (0.57) | KDM1AMAOBMAOALTA4HMAPK14 | |
| Hydrochloric Acid SCHEMBL25342969 | 0.78 | KDM1A (0.54) | KDM1AMAOBMAOAMAPTL3MBTL1 | |
| SCHEMBL31501865 | 0.78 | APP (0.51) | KDM1AMAOBMAOALTA4HMAPK14 | |
| SCHEMBL3915787 | 0.78 | APP (0.51) | KDM1AMAOBMAOALTA4HMAPK14 | |
| SCHEMBL23899537 | 0.78 | KDM1A (0.50) | KDM1AMAOBMAOALTA4HMAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4472739-A1 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. Hoffmann-La Roche AG (CH) | 2024-12-11 | — | — | EP | disclosed |
| WO-2023148129-A1 | IMIDAZOLE MACROCYCLES FOR THE TREATMENT OF AUTOIMMUNE DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2023-08-10 | — | — | WO | disclosed |
| US-8252820-B2 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as PTP-as inhibitors | NOVARTIS AG (CH) | 2012-08-28 | — | — | US | disclosed |
| US-20100035942-A1 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors | NOVARTIS AG (CH) | 2010-02-11 | — | — | US | disclosed |
| EP-1963293-A1 | 1-ORTHOFLUOROPHENYL SUBSTITUTED 1, 2 , 5-THIAZOLIDINEDIONE DERIVATIVES AS PTP-AS INHIBITORS | Novartis AG (CH) | 2008-09-03 | — | — | EP | disclosed |
| WO-2007067612-A1 | 1-ORTHOFLUOROPHENYL SUBSTITUTED 1, 2, 5-THIAZOLIDINEDIONE DERIVATIVES AS PTP-AS INHIBITORS | NOVARTIS AG (CH) | 2007-06-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035942-A1 | 1-orthofluorophenyl substituted 1,2,5-thiazolidinedione derivatives as ptp-as inhibitors | PTPRS, PTPRF, PTPRO | KDM1A 2605/4885MAOB 2135/4885MAOA 2804/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.